2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Naveen Pemmaraju, MD, discusses the potential role of novel therapies in myeloproliferative neoplasms.
Naveen Pemmaraju, MD, associate professor in the Department of Leukemia of the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discusses the potential role of novel therapies in myeloproliferative neoplasms (MPNs).
Oftentimes, patients with MPNs are ineligible for, intolerant of, or resistant to JAK inhibitors, Pemmaraju says. As such, there is a growing need to identify additional therapies in the space.
To date, research is focused on 2 key areas: adding novel agents to JAK inhibitors and introducing completely new agents to the armamentarium, Pemmaraju explains.
Notably, this research may play a role in mitigating the shorter overall survival that is associated with patients who progress on JAK inhibitors in the frontline setting, adds Pemmaraju.
The field awaits additional data with regard to these investigational options, concludes Pemmaraju.